Will Smith and Jada Pinkett Smith are not in a hurry to move back in with each other after reconciling their broken marriage. “Call it what you want. They are living their own lives but haven’ ...

SAN DIEGO, Jan. 30, 2025 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and ...

On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the ...

UBS raised the firm’s price target on Neurocrine (NBIX) to $176 from $162 and keeps a Buy rating on the shares. The firm expects Neurocrine to indicate 50-100 patient enrollment forms for ...

Neurocrine Biosciences (NBIX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset collaboration with Neurocrine Biosciences. Osavampator, formerly known as NBI ...

Neurocrine Biosciences amended its Takeda agreement, gaining exclusive global rights to osavampator for major depressive disorder. Phase 2 data for osavampator showed significant MADRS score ...

Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the amended agreement, Neurocrine will obtain exclusive ...

Visa and Abbott are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These products and services ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24. Paul Matteis has given his Buy rating due to a combination of factors ...